Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
103 hedge funds and large institutions have $42.9M invested in Clovis Oncology, Inc. in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 37 reducing their positions, and 24 closing their positions.
109% more call options, than puts
Call options by funds: $4.99M | Put options by funds: $2.38M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 115 → 103 (-12)
35% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 37
43% less capital invested
Capital invested by funds: $75.6M → $42.9M (-$32.7M)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$2.22M |
| 2 |
ABG
Ally Bridge Group
New York
|
+$832K |
| 3 |
N
Natixis
Paris,
France
|
+$779K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$622K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.58M |
| 3 |
E
Ergoteles
New York
|
-$1.27M |
| 4 |
BlackRock
New York
|
-$1.07M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.02M |
CLVS Hedge Fund Activity: Q3 2022 in Review
103 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2022, worth a combined $42.9M — down 43% from $75.6M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CLVS and 13 opened new positions — a net loss of 11 holders — while 37 trimmed existing stakes and 24 added.
The largest buyer was QVT Financial, adding an estimated $2.22M. The largest seller was Millennium Management, cutting an estimated $6.9M.
- 103 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2022, down from 115 in Q2 2022.
- Funds reported $42.9M of Clovis Oncology, Inc. stock for Q3 2022, down 43% quarter-over-quarter.
- 13 funds opened new Clovis Oncology, Inc. positions in Q3 2022 and 24 closed out, a net change of -11 holders.
- The largest Clovis Oncology, Inc. buyer in Q3 2022 was QVT Financial, an estimated $2.22M added.
- The largest Clovis Oncology, Inc. seller in Q3 2022 was Millennium Management, an estimated $6.9M sold.
Based on aggregated 13F filings for Q3 2022.